CD274 and non-small cell lung carcinoma: Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody CPI targeted against PD-L1 that has been approved for the treatment of patients with stage III NSCLC and as first-line therapy with etoposide and either carboplatin or cisplatin for extensive-stage small cell lung cancer19–23.